Myeloid Therapeutics

We are excited to continue to tell the Myeloid Therapeutics story at several upcoming conferences in September and October. More details can be found here: https://lnkd.in/grVRs2nV #biotech #mRNA

The Myeloid Therapeutics team is looking forward to participating in the Barclays Biotech: 1x1 Private Company Symposium on August 7, 2024. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology. Learn more here: https://lnkd.in/gSj6A_xD   #Biotech #mRNA

Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year. It is also the third leading cause of cancer death. At Myeloid Therapeutics, our mission is to develop RNA therapeutics to conquer cancer - dosing our first patient with MT-303 in our Phase 1 study brings us one step closer to achieving our goal. Thank you to the clinical investigators, study coordinators and participants for helping us advance our research.    Learn more about our clinical trials here: https://lnkd.in/gt-m8NGy   #invivo #oncology #livercancer #clinicaltrials

#BreakingNews. Myeloid Therapeutics’ pipeline of in vivo therapies continues to advance in the clinic! We announced today that we are dosing patients with our second in vivo mRNA CAR, MT-303, a novel GPC3 targeting RNA CAR, in a Phase 1 study for the treatment of advanced hepatocellular carcinoma, or HCC, the most prevalent form of liver cancer. Unlike autologous cell therapies, Myeloid's approach focuses on in vivo programming of immune cells with off-the-shelf mRNA encoded CAR technology.     Learn more here: https://lnkd.in/g_6xtgdQ   #invivo #oncology #livercancer #clinicaltrials

Jerome Chal, Myeloid's SVP and Head of CMC, presents today in Boston at the 2024 Cell & Gene Therapy Summit. He will describe Myeloid's acceleration of in vivo programming of immune cells for patients combating solid tumors. Join us and learn more about Myeloid Therapeutics and our field-leading clinical progress with in vivo CAR/LNPs.    More detail here: https://bit.ly/3WeHMOE #CGT2024 #invivo #RNA #immunotherapy

We are #hiring an Associate Director, Cell Engineering. Check out our website to learn about our exciting journey and unique opportunity to join the team. https://lnkd.in/eFwTdDCd

The Myeloid team had a productive weekend at #ASCO24 meeting with potential partners and clinical collaborators. We also met recently with a patient living with TNBC cancer - for whom new treatment approaches like our MT302 clinical program are needed. We are more hopeful, excited, and motivated than ever to improve the lives of patients with cancer by advancing our next-generation immunotherapies.    See you next year!    #ASCO24 #mRNA #biotech #clinicaloncology

Next week, we are headed to New York for the Jefferies Healthcare Conference Private Biotech Day! Members of the Myeloid Therapeutics management team will be meeting with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology and expanding clinical pipeline.    Learn more here: https://lnkd.in/gXRPyTUW #JefferiesHealthcare #biotech #mRNA

#APVIC 2024 is a global congress that brings together experts in Melbourne, Australia, this week. Discussions ranged in a number of fields where Myeloid Therapeutics shares tremendous expertise, including advanced genetic therapies, RNA manufacturing, immuno-oncology, and drug development. Our CSO, Robert Hofmeister, Ph.D., showcased Myeloid's cutting-edge in vivo mRNA engineering technology and in vivo clinical pipeline.     More details can be found here: https://www.apvic.org/   #APVIC24 #mRNA #invivo #biotech

Our in vivo mRNA CAR, MT-302, continues progressing well in the ongoing clinical studies, with plans for expanded clinical use. Daniel G., PhD, our CEO, recently shared that we are expanding plans for MT-302’s clinical use, given several inherent product advantages for patients. Learn more here: https://lnkd.in/g9xsjxma #biotech #mRNA #ASGCT2024